Different Non-selective β-Blocker Therapy and Risk of Chronic Obstructive Pulmonary Disease

Affiliations

¹ Department of Internal Medicine, Cardinal Tien Hospital and School of Medicine, College of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan.
² Medical Research Center, Cardinal Tien Hospital and School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.
³ Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Taiwan.

Cheng-Yi Wang et al. EClinicalMedicine. 2019.

. 2019 May 8:10:3.

doi: 10.1016/j.eclinm.2019.04.013. eCollection 2019 Apr.

¹ Department of Internal Medicine, Cardinal Tien Hospital and School of Medicine, College of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan.
² Medical Research Center, Cardinal Tien Hospital and School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.
³ Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Taiwan.

No abstract available

References

1. Nielsen A.O., Pedersen L., Sode B.F., Dahl M. β-Blocker therapy and risk of chronic obstructive pulmonary disease – a Danish Nationwide study of 14 million individuals. EClinicalMedicine. 2019;7:21–26. - PMC - PubMed
1. Huang Y.L., Lai C.C., Wang Y.H., Wang C.Y., Wang J.Y., Wang H.C. Impact of selective and nonselective beta-blockers on the risk of severe exacerbations in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2017 Oct 11;12:2987–2996. - PMC - PubMed